Compile Data Set for Download or QSAR
Report error Found 205 Enz. Inhib. hit(s) with all data for entry = 9534
TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242764(US9422299, 30 | US10030025, Compound 30 | US998727...)
Affinity DataIC50: 5nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242764(US9422299, 30 | US10030025, Compound 30 | US998727...)
Affinity DataKi:  7nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112180(CHEMBL3608688 | US9422299, 41 | US10030025, Compou...)
Affinity DataIC50: 7nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242740(US9422299, 1 | US10030025, Compound 1 | US9987274,...)
Affinity DataKi:  11nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112180(CHEMBL3608688 | US9422299, 41 | US10030025, Compou...)
Affinity DataKi:  11nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242741(US9422299, 2 | US10030025, Compound 2 | US9987274,...)
Affinity DataIC50: 12nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242741(US9422299, 2 | US10030025, Compound 2 | US9987274,...)
Affinity DataKi:  15nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242740(US9422299, 1 | US10030025, Compound 1 | US9987274,...)
Affinity DataIC50: 16nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112244(CHEMBL3608680 | US9422299, 5 | US10030025, Compoun...)
Affinity DataIC50: 18nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112181(CHEMBL3608687 | US9422299, 3 | US10030025, Compoun...)
Affinity DataKi:  19nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242742(US9422299, 4 | US10030025, Compound 4 | US9987274,...)
Affinity DataIC50: 19nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242742(US9422299, 4 | US10030025, Compound 4 | US9987274,...)
Affinity DataKi:  20nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242746(US9422299, 9 | US10030025, Compound 9 | US9987274,...)
Affinity DataIC50: 21nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112244(CHEMBL3608680 | US9422299, 5 | US10030025, Compoun...)
Affinity DataKi:  23nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242743(US9422299, 6 | US10030025, Compound 6 | US9987274,...)
Affinity DataKi:  24nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242772(US9422299, 38 | US10030025, Compound 38 | US998727...)
Affinity DataKi:  26nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242745(US9422299, 8 | US10030025, Compound 8 | US9987274,...)
Affinity DataKi:  26nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242744(US9422299, 7 | US10030025, Compound 7 | US9987274,...)
Affinity DataKi:  26nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242773(US9422299, 39 | US10030025, Compound 39 | US998727...)
Affinity DataKi:  28nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242744(US9422299, 7 | US10030025, Compound 7 | US9987274,...)
Affinity DataIC50: 30nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242743(US9422299, 6 | US10030025, Compound 6 | US9987274,...)
Affinity DataIC50: 30nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242746(US9422299, 9 | US10030025, Compound 9 | US9987274,...)
Affinity DataKi:  30nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242747(US9422299, 10 | US10030025, Compound 10 | US998727...)
Affinity DataKi:  31nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242773(US9422299, 39 | US10030025, Compound 39 | US998727...)
Affinity DataIC50: 32nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US9422299, 11 | US10030025, Compou...)
Affinity DataKi:  32nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM50112181(CHEMBL3608687 | US9422299, 3 | US10030025, Compoun...)
Affinity DataIC50: 32nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242745(US9422299, 8 | US10030025, Compound 8 | US9987274,...)
Affinity DataIC50: 33nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242772(US9422299, 38 | US10030025, Compound 38 | US998727...)
Affinity DataIC50: 34nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242768(US9422299, 34 | US10030025, Compound 34 | US998727...)
Affinity DataKi:  38nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242775(US9422299, 42 | US10030025, Compound 42 | US998727...)
Affinity DataIC50: 39nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242749(US9422299, 13 | US10030025, Compound 13 | US998727...)
Affinity DataKi:  40nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242771(US9422299, 37 | US10030025, Compound 37 | US998727...)
Affinity DataKi:  41nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242750(US9422299, 14 | US10030025, Compound 14 | US998727...)
Affinity DataKi:  42nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242770(US9422299, 36 | US10030025, Compound 36 | US998727...)
Affinity DataKi:  43nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242749(US9422299, 13 | US10030025, Compound 13 | US998727...)
Affinity DataIC50: 44nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242766(US9422299, 32 | US10030025, Compound 32 | US998727...)
Affinity DataIC50: 44nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242777(US9422299, 44 | US10030025, Compound 44 | US998727...)
Affinity DataKi:  45nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242751(US9422299, 15 | US10030025, Compound 15 | US998727...)
Affinity DataKi:  45nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242775(US9422299, 42 | US10030025, Compound 42 | US998727...)
Affinity DataKi:  48nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242752(US9422299, 16 | US10030025, Compound 16 | US998727...)
Affinity DataKi:  49nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242751(US9422299, 15 | US10030025, Compound 15 | US998727...)
Affinity DataIC50: 50nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242753(US9422299, 17 | US10030025, Compound 17 | US998727...)
Affinity DataIC50: 50nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242753(US9422299, 17 | US10030025, Compound 17 | US998727...)
Affinity DataKi:  51nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242771(US9422299, 37 | US10030025, Compound 37 | US998727...)
Affinity DataIC50: 52nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242754(US9422299, 18 | US10030025, Compound 18 | US998727...)
Affinity DataKi:  54nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242769(US9422299, 35 | US10030025, Compound 35 | US998727...)
Affinity DataIC50: 54nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242755(US9422299, 19 | US10030025, Compound 19 | US998727...)
Affinity DataKi:  56nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242747(US9422299, 10 | US10030025, Compound 10 | US998727...)
Affinity DataIC50: 56nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242750(US9422299, 14 | US10030025, Compound 14 | US998727...)
Affinity DataIC50: 57nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM242770(US9422299, 36 | US10030025, Compound 36 | US998727...)
Affinity DataIC50: 58nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

Displayed 1 to 50 (of 205 total ) | Next | Last >>
Jump to: